Cardiff Oncology, Inc. (NASDAQ: CRDF) is a Healthcare company (Biotechnology) with a market capitalization of $66M. The Maz Rating grades it against the other companies in its sector.
Cardiff Oncology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.85, Cardiff Oncology, Inc. trades at 115.9x sales and 2.3x book value. Over the last twelve months it generated about $568129 of revenue and a net loss of $43M. It runs a gross margin of -1579.8%, an operating margin of -7068.2% and a net margin of -6735.2%. It shows return on equity of -111.8%, return on invested capital of -139.3% and a free cash flow yield of -61.7%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 4.21. Over the past 52 weeks the share price ranged from $0.71 to $3.31, with a beta of 1.56.
Cardiff Oncology, Inc. does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 8 Buy, 6 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Cardiff Oncology, Inc. (CRDF) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 48.0% / 30% · Interest income / Revenue 212.3% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 48.0% / 33% · Receivables / Mkt Cap (36m) 0.13% / 49% · Interest income / Revenue 212.3% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 48.0% / 33.33% · Receivables / Mkt Cap (24m) 0.13% / 33.33% · Interest income / Revenue 212.3% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 93.4% / 33.33% · Receivables / Avg Assets (4Q) 0.35% / 33.33% · Interest income / Revenue 212.3% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 92.8% / 33.33% · (Cash+Recv) / Total Assets 93.0% / 33.33% · Interest income / Revenue 212.3% / 5% | Fail |
No. As of September 2026, Cardiff Oncology, Inc. (CRDF) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Cardiff Oncology, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 212.3% of each dividend: Cardiff Oncology, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.